Leqembi

News

Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.

News

Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.

News

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

News

A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.

News

Eisai and Biogen have another chance to convince NICE that the NHS should cover the cost of Alzheimer's therapy Leqembi.

News

Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.